CClinicalTrials.gg
CompletedNCT04781712MMHTRUpdated Oct 26, 2022

Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer

An interventional study of Modular mHealth for Tailored Rehabilitation in Breast Cancer, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to female participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Apr 2019, registered Feb 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Female
01

Study summary

This study investigated the feasibility of the novel modular mobile health (mHealth) for personalized rehabilitation and explored the participants' satisfaction and app data during treatment of breast cancer.

Read the detailed description

This is prospective, feasible, parallel study in post-operative patients with breast cancer and during treatment. Disability of Arm, Shoulder, Hands (DASH), Physical activity data (IPAQ-SF), Physical measurement such as hand grip strength, body mass index (BMI), muscle mass, and differences in arm circumference, PRO-CTCAE, Distress Thermometer, needs and satisfaction in app, personal health record of app (exercise, daily step count, etc.) Measure will be evaluated on 1-month, 2-month, 4-month, 6-month, 9-month, and 12-month after POD.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 44 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Unilateral breast cancer at TNM stage 0 \~ III
  • Patients who will undergo the treatment (chemotherapy, radiation therapy, and hormone therapy) after surgery
  • Patients who had a mobile phone (Android or iOS)

Exclusion criteria

Exclusion Criteria:

  • Patients who have metastases or recurrence to other organs were excluded
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Self-management using mHealth

    Self-management (physical activity, sleep, exercise, education, etc.) using mHealth

    Behavioral: Modular mHealth for Tailored Rehabilitation

  • No intervention
    Exercise using brochure

    Only exercise using brochure

Interventions

  • BehavioralModular mHealth for Tailored Rehabilitation

    an individually tailored self-management through the mHealth app with a smart band worn on the wrist

    Also known as: mHealth

06

What researchers measure

Primary outcomes

  1. satisfaction score in app contents

    satisfaction score in app contents, Likert scale (5-point, higher scores mean a better)

    Time frame: 1 to 12month

  2. Needs score in app contents

    Needs score in app contents, Likert scale (5-point, higher scores mean a better)

    Time frame: 1 to 12month

  3. DASH (Disabilities of Arm, Shoulder, Hands)

    Change from Baseline DASH score at 12 months, higher scores mean a worse (0-100)

    Time frame: 1 month, 2month, 4month, 6month, 9month, 12month

Secondary outcomes

  1. Physical measurement (handgrip strength)

    Handgrip strength (kg)

    Time frame: 1 to 12month

  2. Physical measurement (of body composition, BMI)

    Body mass index

    Time frame: 1 to 12month

  3. Physical measurement (of body composition, muscle mass)

    muscle mass

    Time frame: 1 to 12month

  4. Physical measurement (upper extremity volume)

    differences in arm circumference

    Time frame: 1 to 12month

  5. Physical activity (IPAQ-SF Questionnaire)

    Total METs within recent 7 days (vigorous, moderate, walking, sitting), higher values mean a better

    Time frame: 1 to 12month

  6. PRO-CTCAE (patients reported outcomes)

    Symptoms during treatment

    Time frame: 1 to 12month

  7. Distress thermometer (distress level)

    Distress level during treatment, higher scores mean a worse (0-10)

    Time frame: 1 to 12month

  8. App use data (personal health record)_Exercise compliance rate

    Exercise time, higher values mean a better

    Time frame: 1 to 12month

  9. App use data (personal health record)_Physical activity change

    daily step count (number), higher values mean a better physical activity

    Time frame: 1 to 12month

  10. App use data (personal health record)_interest of contents

    contents view (number), higher values mean a better compliance rate

    Time frame: 1 to 12month

  11. App use data (personal health record)_sleep

    sleep compliance rate (%), higher values mean a better compliance rate

    Time frame: 1 to 12month

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Gangnam-gu 06351, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04781712
Lead sponsor
Samsung Medical Center
Responsible party
JiHye Hwang (Professor, Samsung Medical Center) — Principal investigator
First posted
Mar 4, 2021
Start date
Apr 22, 2019
Primary completion
Mar 30, 2021
Completion
Mar 30, 2021
Last update
Oct 26, 2022

Study contacts

JIHYE HWANG, Professor
study chair · Physical & Rehabilitation Medicine Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion